Sipai Health Technology Co., Ltd, also known as Medbanks, is set to make an initial public offering (IPO) of 9.92 million shares to the Hong Kong Stock Exchange (HKSE), priced at HKD 18.6 (USD 2.39) per share. The online health platform expects to take home HKD 184 million (USD 23.66 million), or HKD 120.4 million (USD 15.48 million) in net proceeds.
Business Overview and Services
Medbanks’ special drug pharmacy business line includes special drug pharmacy and value-added pharmacist services, targeting cancer and other major illnesses. The company, the first and only national special drug management platform in China, boasts a total of 103 special drug pharmacies, including 76 designated private medical insurance pharmacies and 47 eligible as a major illness medical insurance dual channel.
SMO Services and Health Insurance Business
In addition, the company provides SMO services assisting physician study. As of June 30, 2022, its experimental centers in 87 cities have provided services for 289 customers, covering 27 provincial cancer hospitals and five national cancer treatment centers. Its health insurance service business boasts a strong supplier network, which is connected with special drug pharmacies, covering about 23.9 million individual members and 876 corporate customers.
Financial Performance
Medbanks generated RMB 2.7 billion (USD 386.76 million) and RMB 3.474 billion (USD 497.63 million) in revenues in 2021 and the first six months of 2022 respectively, alongside RMB 3.748 million (USD 536.8 million) and RMB 344 (USD 49.2 million) in million pre-tax losses.-Fineline Info & Tech
